Letters, Testimony & Comments

November 15, 2001
Regarding funding for the U.S. Patent and Trademark Office
October 29, 2001
By Carl B. Feldbaum At a time when national security is understandably monopolizing Congress's legislative calendar, as well as the energies of the federal agencies that regulate biotechnology, I am pleased to report that the biotechnology...
October 23, 2001
TESTIMONY OF STEPHEN G. SUDOVAR President and CEO EluSys Therapeutics, Inc. 10 Bloomfield Ave. Pine Brook, NJ 07058 973-808-0222 (phone) 973-808-0322 (fax) Committee on Government Reform Subcommittee on National Security, Veterans Affairs...
October 23, 2001
TESTIMONY U.S. House of Representatives Committee on Government Reform Subcommittee on National Security, Veterans Affairs, and International Relations Hearing on Biological Warfare Defense Vaccine Research & Development Programs 10:00 A...
October 1, 2001
Outling BIO opposition to generic biologic and pediatric rule codification amendments on pediatric exclusity bill.
October 1, 2001
Outlining BIO opposition to generic biologic and pediatric rule codification amendments on pediatric exclusivity bill
September 26, 2001
The Honorable Michael Harris, M.P.P. Premier of Ontario Legislative Assembly of Ontario Room 281 Legislative Building Toronto, Ontario M7A 1A1 Dear Premier Harris: I read with concern your remarks about modifying Canadian patent laws to...
July 26, 2001
Honorable Michael Bilirakis Chairman Subcommittee on Health Committee on Energy and Commerce U.S. House of Representatives 2125 Rayburn Building Washington, DC 20015 Dear Mr. Chairman: On June 13, your Subcommittee held a hearing...
July 13, 2001
Dan Eramian, Vice President Communications Biotechnology Industry Organization Athersys Cleveland, Ohio July 13, 2001 Let me start by telling you a little about the Biotechnology Industry Organization, or BIO. We are the national...
July 11, 2001
Written Statement of J. Craig Venter, PhD, President, Celera Genomics On Behalf of The Biotechnology Industry Organization (BIO) Before the Subcommittee on Consumer Protection US House Committee on Energy and Commerce July 11, 2001 Good...
June 20, 2001
Good afternoon. My name is Thomas Okarma. I am the President and CEO of Geron Corporation in Menlo Park, California. Geron is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutic and diagnostic products for...
June 19, 2001
Good afternoon. My name is Thomas Okarma. I am the President and CEO of Geron Corporation in Menlo Park, California. Geron is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutic and diagnostic products...
May 10, 2001
Executive Summary The Biotechnology Industry Organization (BIO) supports amendment of the current reexamination authority to enhance patent quality. Congress established the patent reexamination system in 1980 as an ex parte proceeding that could be...
May 4, 2001
Acting Undersecretary of Commerce and Acting Director of the United States Patent and Trademark Office Regarding Patent Law Harmonization
May 2, 2001
Good afternoon. My name is Carl Feldbaum. I am the president of the Biotechnology Industry Organization, otherwise known as BIO. BIO represents more than 950 biotechnology companies, academic institutions and state biotechnology centers in all 50 U....
April 18, 2001
The Biotechnology Industry Organization (BIO) is pleased to submit comments to the Food and Drug Administration (FDA) on the proposed rule "Availability for Public Disclosure and Submission to FDA for Public Disclosure of Certain Data and...
April 18, 2001
The Biotechnology Industry Organization (BIO) is pleased to submit comments to the Food and Drug Administration (FDA) on the proposed rule "Availability for Public Disclosure and Submission to FDA for Public Disclosure of Certain Data and...